STAAR Surgical Q2 ICL sales record $93.1M; GAAP EPS $0.12; guides FY ICL sales $320M-$325M

STAAR SURGICAL CO

2023-Q1 EPS reported $0.18 revenue$165,834,000

Record ICL sales of $93.1M, +19% YoY; ICL units +21% YoY.
Net sales $92.3M (+14% YoY); GAAP EPS $0.12 vs $0.26 prior year; adjusted ICL EPS $0.19.
Updated FY2023 ICL sales outlook to $320M-$325M (midpoint ~20% growth).
APAC ICL sales grew 26% YoY; U.S. ICL sales +10% vs industry -15%.
Gross margin 76.6% vs 78.8% prior year; cash & investments $209.5M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

STAAR SURGICAL CO reported the second quarter ended June 30, 2023 results: revenue $92.3 million, net income $6.1 million or $0.12 per diluted share, EPS $0.12 per diluted share. Guidance lowered.

Period: the second quarter ended June 30, 2023
Revenue: $92.3 million
Net income: $6.1 million or $0.12 per diluted share
EPS: $0.12 per diluted share
Guidance: lowered
Result: reported results

Exact text from the filing

and marketer of implantable lenses for the eye, today reported financial results for the second quarter ended June 30, 2023. Second Quarter 2023 Overview • Net Sales of $92.3 Million Up 14% includes a $0.7 Million sales reduction related to Other Products • Record ICL Sales of $93.1 Million Up 19% Y/Y and Up 20% Y/Y in Constant Currency • ICL Units Up 21% Y/Y

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

STAAR SURGICAL CO filing history →

Source: SEC EDGAR

accession 0001193125-23-201709

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.